Optimized formulation significantly enhances LABL-Fc-MOGR5 stability, preventing aggregation and fragmentation for clinical development
Background
Developing peptide therapeutics for conditions like Multiple Sclerosis (MS), particularly primary progressive multiple sclerosis, often faces significant hurdles due to poor physical and chemical stability. LABL-Fc-MOGR5, a promising bifunctional peptide inhibitor designed to modulate immune responses, has been hindered by rapid precipitation under standard formulation conditions. This instability compromises its therapeutic potential by affecting shelf-life, bioavailability, and consistent dosing, necessitating robust formulation strategies to enable its progression to clinical trials.
Study Design
Researchers implemented a three-phase formulation strategy to enhance the conformational and colloidal stability of LABL-Fc-MOGR5. Phase 1 screened 96 formulations across pH, buffer systems, and excipients using intrinsic fluorescence differential scanning fluorometry and polyethylene glycol (PEG) solubility assays. Phase 2 employed a definitive screening design to evaluate buffer type, excipients, and surfactant concentration at reduced protein concentrations in 96-well plates. Phase 3 compared the lead formulation from Phase 2 with a control at higher protein concentrations in glass vials, assessing aggregation, fragmentation, and subvisible particle formation.
Results
The Phase 1 study revealed LABL-Fc-MOGR5's pronounced sensitivity to pH and ionic strength. Divalent anionic buffers, such as citrate and succinate, along with excipients like sucrose and hydroxypropyl-β-cyclodextrin, substantially reduced the peptide's aggregation propensity. Through statistical modeling in Phase 2, an optimized formulation was identified: 10 mM sodium acetate, pH 5.3, 125 mM sucrose, 150 mM HBP-LB-βCD, and 0.025% polysorbate 80. This optimized formulation demonstrated significantly enhanced resistance to aggregation, fragmentation, and subvisible particle formation when subjected to accelerated stress conditions, compared to the control formulation.
The optimized formulation provided a significantly enhanced stability profile, crucial for advancing LABL-Fc-MOGR5 toward clinical evaluation.
Key Findings
- LABL-Fc-MOGR5 stability is highly sensitive to pH and ionic strength.
- Divalent anionic buffers (citrate, succinate) and excipients (sucrose, hydroxypropyl-β-cyclodextrin) significantly reduce aggregation.
- An optimized formulation (10 mM sodium acetate, pH 5.3, 125 mM sucrose, 150 mM HBP-LB-βCD, 0.025% polysorbate 80) was identified.
- The optimized formulation markedly improved resistance to aggregation, fragmentation, and subvisible particle formation under accelerated stress.
Why It Matters
This work provides a critical step forward for LABL-Fc-MOGR5's clinical translation, addressing a major barrier to its development. A stable formulation is paramount for ensuring consistent dosing, predictable pharmacokinetics, and reliable efficacy in clinical trials and eventual patient use. For peptide users and biohackers, this highlights the importance of formulation science in realizing the therapeutic potential of complex peptides, suggesting that even promising compounds can fail without proper stabilization. The detailed excipient and buffer choices offer insights into rational design for other challenging peptide therapeutics, potentially informing future compounding or storage protocols.
labl-fc-mogrs
multiple-sclerosis
formulation
stability
peptide-inhibitor
drug-development